GBM Clinical Trials

17 recruiting

GBM Trials at a Glance

45 actively recruiting trials for gbm are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in New York, Boston, and Phoenix. Lead sponsors running gbm studies include Northwell Health, Institute of Cancer Research, United Kingdom, and Peking University Third Hospital.

Treatments under study

About GBM Clinical Trials

Looking for clinical trials for GBM? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new GBM trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about GBM clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 1

Sonodynamic Therapy in Patients With Recurrent GBM

GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Glioblastoma (GBM)
Diakonos Oncology Corporation180 enrolled16 locationsNCT06805305
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

Glioblastoma (GBM)
Myosin Therapeutics Inc.36 enrolled3 locationsNCT07185880
Recruiting
Phase 3

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Brain TumorGlioblastomaGBM+1 more
Ivy Brain Tumor Center450 enrolled95 locationsNCT06388733
Recruiting

Mental Health and Suicidality in Glioblastoma Patients in Germany

Glioblastoma (GBM)
University Hospital, Essen176 enrolled6 locationsNCT07409584
Recruiting
Phase 2

Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma

Glioblastoma (GBM)
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT07511725
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

GlioblastomaGlioblastoma (GBM)High-Grade Glioma (WHO III-IV)
Medical University of Warsaw35 enrolled2 locationsNCT07488754
Recruiting
Phase 2

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

GlioblastomaGBM
Alpheus Medical, Inc.103 enrolled8 locationsNCT07225621
Recruiting
Phase 1Phase 2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Not Applicable

WBSI Guided Personalized Delivery of TTFields

GBMTumor, BrainGlioma Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine155 enrolled2 locationsNCT05086497
Recruiting
Not Applicable

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM)Astrocytoma, Grade IV
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07459101
Recruiting
Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Brain MetastasasesGlioblastoma (GBM)
Nader Sanai15 enrolled1 locationNCT07268053
Recruiting

Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach

GlioblastomaGlioblastoma (GBM)Glioblastoma - Category+1 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta30 enrolled1 locationNCT07420543
Recruiting
Phase 1Phase 2

5G-PEARL: Paxalisib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary Gliomas
Institute of Cancer Research, United Kingdom64 enrolled1 locationNCT07391215
Recruiting
Phase 1

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260